NCT04443244View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

November 18, 2020

Study Completion Date

July 16, 2021

Conditions
Benign Masseteric Hypertrophy
Interventions
DRUG

Botulinum Toxin Type A Injection (Botulax®) 24Units

Experimental: Botulax® 24Units

DRUG

Botulinum Toxin Type A Injection (Botulax®) 48Units

Experimental: Botulax® 48Units

DRUG

Botulinum Toxin Type A Injection (Botulax®) 72Units

Experimental: Botulax® 72Units

DRUG

Botulinum Toxin Type A Injection (Botulax®) 96Units

Experimental: Botulax® 96Units

OTHER

Normal Saline

Placebo Comparator: Normal Saline

Trial Locations (1)

Unknown

Hugel, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT04443244 - Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy | Biotech Hunter | Biotech Hunter